Topic: Pay for delay

Value Drug has once again failed to provide evidence that certifying a class of purchasers of wholesale gout medication is warranted, a Pennsylvania federal judge has said.

02 March 2023

A California federal court has thrown out product-hopping claims against Gilead Sciences relating to one of its HIV treatments, although the drugmaker and several others failed to escape allegations they agreed anticompetitive non-competes and pay-for-delay schemes.

23 February 2023

The Senate Judiciary Committee has advanced five bipartisan bills aiming to promote competition and reduce drug prices in the pharmaceutical industry.

13 February 2023

A Pennsylvania federal judge has refused to certify a class of wholesale purchasers of a gout treatment medicine, finding that the claim against several major drugmakers is based on faulty expert testimony that does not hold up to rigorous analysis.

28 November 2022

Celgene, Bristol-Myers Squibb and two generic drugmakers engaged in a years-long conspiracy to hinder generic competition for a rare cancer medication, Walgreens and Kroger Pharmacies have alleged.

07 November 2022

A California federal judge has certified eight out of nine proposed classes of purchasers in the HIV antitrust litigation, rebuffing drugmakers’ claims that the plaintiffs “lack typicality and adequacy” to recover damages on a classwide basis.

04 November 2022

GCR Live: Antitrust in Pharmaceuticals is returning to New York in December, with panels discussing killer acquisitions, the diverging enforcement of pay-for-delay deals and the Inflation Reduction Act.

21 October 2022

Glenmark Pharmaceuticals and Merck should have to face pay-for-delay claims over the cholesterol-lowering drug Zetia at trial, a federal magistrate judge has said.

07 September 2022

The UK’s Competition Appeal Tribunal can oversee a fair appeal process without holding a hearing, its president has said while rejecting drugmakers' claims that oral submissions are a fundamental part of their appeals against excessive pricing penalties.

25 July 2022

The European Court of Justice should set aside a General Court decision that found agreements between Servier and generics drugmaker Krka did not constitute by-object or by-effect restrictions of competition, EU advocate general Juliane Kokott has said.

14 July 2022